Paper Details

  1. Home
  2. Paper Details

Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Author: AdesL, AttarE C, BraunT, BroutinS, ClappierE, De BottonS, DelahousseJ, DuchmannM, FenauxP, FrattiniM, ItzyksonR, MarceauA, MicolJ B, PaciA, PascalL, PasquierF, Penard-LacroniqueV, PreudhommeC, QuivoronC, RaffouxE, RahmeR, RennevilleA, RossignolJ, SaadaV, SimonL, UzunovM, VidalV, WillekensC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study investigated the clinical impact of azacitidine (AZA) in myeloid neoplasms (MNs) with IDH1/2 mutations and the potential of serum 2HG as a marker of response to AZA. While AZA showed some response rate, it was not consistently effective, and serum 2HG levels did not reliably predict response.
Paper Details　
Original Abstract of the Article :
Isocitrate dehydrogenase 1 (<i>IDH1</i>) and 2 (<i>IDH2</i>) mutations in Myeloid Neoplams (MNs) exhibit DNA hypermethylation <i>via</i> 2-hydroxyglutarate (2HG) over-production. Clinical impact of azacitidine (AZA) remains inconsistent in <i>IDH1/2</i>-mutated MNs and the potential of serum 2HG as ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/10428194.2020.1832661

データ提供：米国国立医学図書館（NLM）

Azacitidine and IDH1/2 Mutated AML/MDS: A New Path in the Desert of Cancer

The field of hematology is often a search for new frontiers in the battle against cancer. This study delves into the effectiveness of azacitidine (AZA) in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with IDH1/2 mutations.

A Novel Approach: Targeting the Mutated Landscape

The study investigated the clinical impact of AZA in patients with IDH1/2 mutations, exploring whether serum 2-hydroxyglutarate (2HG) could serve as a biomarker for response to treatment.

Navigating the Complexities of Treatment Response

The findings revealed a 28% overall response rate to AZA, including 15% complete remission. However, the study also highlighted the complexities of treatment response, finding that DNMT3A mutations were associated with shorter overall survival.

Dr. Camel's Conclusion

This study provides valuable insights into the use of AZA in treating AML and MDS with IDH1/2 mutations. It emphasizes the importance of considering the unique genetic landscape of each patient. It's a journey of discovery, like a camel navigating a vast and unpredictable desert, where every step reveals new information that shapes our understanding of cancer treatment.

Date :
  1. Date Completed 2021-04-27
  2. Date Revised 2021-04-27
Further Info :

Pubmed ID

33043739

DOI: Digital Object Identifier

10.1080/10428194.2020.1832661

Related Literature

Article Analysis
・Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.